JP2023539501A5 - - Google Patents
Info
- Publication number
- JP2023539501A5 JP2023539501A5 JP2023513787A JP2023513787A JP2023539501A5 JP 2023539501 A5 JP2023539501 A5 JP 2023539501A5 JP 2023513787 A JP2023513787 A JP 2023513787A JP 2023513787 A JP2023513787 A JP 2023513787A JP 2023539501 A5 JP2023539501 A5 JP 2023539501A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- bispecific antibody
- antibody
- vegf
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010897917.1A CN114106190B (zh) | 2020-08-31 | 2020-08-31 | 一种抗vegf/pd-l1双特异性抗体及其用途 |
| CN202010897917.1 | 2020-08-31 | ||
| PCT/CN2021/115308 WO2022042719A1 (zh) | 2020-08-31 | 2021-08-30 | 抗vegf-抗pd-l1双特异性抗体、其药物组合物及用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023539501A JP2023539501A (ja) | 2023-09-14 |
| JP2023539501A5 true JP2023539501A5 (enExample) | 2024-09-03 |
Family
ID=80354674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513787A Pending JP2023539501A (ja) | 2020-08-31 | 2021-08-30 | 抗ｖｅｇｆ－抗ｐｄ－ｌ１二重特異性抗体、その医薬組成物およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12325759B2 (enExample) |
| EP (2) | EP4729545A1 (enExample) |
| JP (1) | JP2023539501A (enExample) |
| KR (1) | KR20230061433A (enExample) |
| CN (2) | CN114106190B (enExample) |
| AU (1) | AU2021334042A1 (enExample) |
| CA (1) | CA3192812A1 (enExample) |
| MX (1) | MX2023002331A (enExample) |
| WO (1) | WO2022042719A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11407832B2 (en) | 2018-12-03 | 2022-08-09 | Immuneonco Biopharmaceuticals (Shanghai) Inc. | Recombinant protein targeting PD-L1 and VEGF |
| CN116731188B (zh) * | 2022-03-02 | 2025-02-14 | 三优生物医药(上海)有限公司 | 抗pd-l1和vegf双特异性抗体及其应用 |
| CN114736303A (zh) * | 2022-03-17 | 2022-07-12 | 英诺湖医药(杭州)有限公司 | 抗pd-l1和4-1bb的双功能抗体及其医药用途 |
| CN117186238A (zh) * | 2022-05-31 | 2023-12-08 | 宜明昂科生物医药技术（上海）股份有限公司 | 靶向pd-l1和vegf的重组融合蛋白及其制备和用途 |
| CN119654350A (zh) * | 2022-08-09 | 2025-03-18 | 上海济煜医药科技有限公司 | 一种靶向pd-l1和vegf的抗体及其应用 |
| CR20250254A (es) * | 2022-12-29 | 2026-01-12 | Shanghai Henlius Biologics Co Ltd | Anticuerpos anti-pdl1/vegf y métodos de uso |
| WO2025157267A1 (zh) * | 2024-01-25 | 2025-07-31 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双特异性抗体的医药用途 |
| WO2025184858A1 (en) | 2024-03-07 | 2025-09-12 | Biotheus Inc. | Combination therapy comprising a bispecific anti-vegf-a and anti-pd-l1 antibody and a chemotherapy for cancer treatment |
| WO2025185161A1 (en) | 2024-03-07 | 2025-09-12 | Biotheus Inc. | Combination therapy comprising a bispecific anti-vegf-a and anti-pd-l1 antibody and a chemotherapy for cancer treatment |
| WO2025185733A1 (en) | 2024-03-07 | 2025-09-12 | Biotheus Inc. | Combination therapy comprising a pd-1/pd-l1 and vegf/vegfr binding agent and a chemotherapy for cancer treatment |
| CN120025456B (zh) * | 2024-03-13 | 2025-11-07 | 寻济生物科技（北京）有限公司 | 一种抗vegfa融合构建体及其制备方法和应用 |
| CN121324641B (zh) * | 2025-12-15 | 2026-04-21 | 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） | 一种检测内罗毕羊病病毒的试剂盒 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| PT971959E (pt) | 1997-04-07 | 2006-05-31 | Genentech Inc | Anticorpos humanizados e metodos para formar anticorpos humanizados |
| KR100816621B1 (ko) * | 1997-04-07 | 2008-03-24 | 제넨테크, 인크. | 항-ｖｅｇｆ 항체 |
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| CA2451998A1 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | Anti-a.beta. antibodies |
| US8188223B2 (en) * | 2005-05-18 | 2012-05-29 | Ablynx N.V. | Serum albumin binding proteins |
| US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| CN103965363B (zh) | 2013-02-06 | 2021-01-15 | 上海白泽生物科技有限公司 | 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途 |
| BR112016014952A2 (pt) | 2014-02-10 | 2017-09-19 | Merck Patent Gmbh | Inibição direcionada de tgfbeta |
| CN106397592A (zh) * | 2015-07-31 | 2017-02-15 | 苏州康宁杰瑞生物科技有限公司 | 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白 |
| WO2017136562A2 (en) | 2016-02-02 | 2017-08-10 | Kadmon Corporation, Llc | Bispecific binding proteins for pd-l1 and kdr |
| CN107216389B (zh) | 2016-03-18 | 2022-03-29 | 和迈生物科技有限公司 | 抗pd-l1纳米抗体及其编码序列和用途 |
| NL2017267B1 (en) * | 2016-07-29 | 2018-02-01 | Aduro Biotech Holdings Europe B V | Anti-pd-1 antibodies |
| MA49279A (fr) | 2017-03-22 | 2020-02-05 | Hoffmann La Roche | Compositions d'anticorps optimisées pour le traitement de troubles oculaires |
| CN109096396B (zh) | 2017-06-20 | 2022-01-04 | 华兰生物工程股份有限公司 | 一种抗pd-l1人源化纳米抗体及其应用 |
| EP3710480A4 (en) | 2017-11-17 | 2021-12-15 | Nanjing Legend Biotech Co., Ltd. | SINGLE-DOMAIN ANTIBODIES AND VARIANTS OF THEM DIRECTED AGAINST PD-L1 |
| CA3092421A1 (en) | 2018-03-01 | 2019-09-06 | Vrije Universiteit Brussel | Human pd-l1-binding immunoglobulins |
| KR20200144094A (ko) | 2018-03-02 | 2020-12-28 | 파이브 프라임 테라퓨틱스, 인크. | B7-h4 항체 및 이의 사용 방법 |
| CN110305210B (zh) | 2018-03-27 | 2023-02-28 | 信达生物制药(苏州)有限公司 | 新型抗体分子、其制备方法及其用途 |
| WO2019184909A1 (zh) * | 2018-03-27 | 2019-10-03 | 信达生物制药(苏州)有限公司 | 新型抗体分子、其制备方法及其用途 |
| CN110835375B (zh) * | 2018-08-16 | 2021-04-06 | 上海洛启生物医药技术有限公司 | 一种抗pd-1/egfr双特异性抗体及其用途 |
| CN109053895B (zh) | 2018-08-30 | 2020-06-09 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 |
| US11407832B2 (en) * | 2018-12-03 | 2022-08-09 | Immuneonco Biopharmaceuticals (Shanghai) Inc. | Recombinant protein targeting PD-L1 and VEGF |
| TWI793395B (zh) * | 2019-01-25 | 2023-02-21 | 大陸商信達生物製藥（蘇州）有限公司 | 結合ｐｄ-ｌ１和ｏｘ４０的雙特異性抗體 |
| CN109942712B (zh) | 2019-04-01 | 2022-12-20 | 华博生物医药技术（上海）有限公司 | 抗pd-l1/vegf双功能抗体及其用途 |
| CN110003333B (zh) | 2019-04-12 | 2022-11-18 | 深圳普瑞金生物药业股份有限公司 | 多肽、pd-l1单域抗体、核苷酸序列及试剂盒 |
| CN110563849B (zh) * | 2019-08-09 | 2022-09-09 | 安徽瀚海博兴生物技术有限公司 | 一种抗vegf-抗pd1双特异性抗体 |
| CN115947846A (zh) * | 2019-09-12 | 2023-04-11 | 普米斯生物技术(珠海)有限公司 | 一种抗pd-l1纳米抗体及其衍生物和用途 |
| CN112646031B (zh) * | 2019-10-10 | 2021-12-07 | 天境生物科技(上海)有限公司 | 抗4-1bb纳米抗体及其用途 |
| EP4093765A4 (en) * | 2020-01-21 | 2023-06-28 | Wuxi Biologics (Shanghai) Co. Ltd. | A bispecific anti-pd-l1/vegf antibody and uses thereof |
| CN114539415B (zh) * | 2020-11-24 | 2024-02-02 | 普米斯生物技术(珠海)有限公司 | 一种抗PD-L1/VEGF/TGF-β多特异性抗体及其用途 |
-
2020
- 2020-08-31 CN CN202010897917.1A patent/CN114106190B/zh active Active
-
2021
- 2021-08-30 MX MX2023002331A patent/MX2023002331A/es unknown
- 2021-08-30 EP EP25208939.6A patent/EP4729545A1/en active Pending
- 2021-08-30 US US18/023,701 patent/US12325759B2/en active Active
- 2021-08-30 KR KR1020237010695A patent/KR20230061433A/ko active Pending
- 2021-08-30 AU AU2021334042A patent/AU2021334042A1/en active Pending
- 2021-08-30 JP JP2023513787A patent/JP2023539501A/ja active Pending
- 2021-08-30 EP EP21860551.7A patent/EP4209513A4/en active Pending
- 2021-08-30 WO PCT/CN2021/115308 patent/WO2022042719A1/zh not_active Ceased
- 2021-08-30 CN CN202180052341.1A patent/CN116261595A/zh active Pending
- 2021-08-30 CA CA3192812A patent/CA3192812A1/en active Pending
-
2025
- 2025-05-12 US US19/205,772 patent/US20250297034A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023539501A5 (enExample) | ||
| CN117946274B (zh) | 抗cd73抗体及其应用 | |
| JP2022515318A5 (enExample) | ||
| KR101971770B1 (ko) | 이중특이성 항체 및 이의 용도 | |
| CN119161491A (zh) | 双特异性重组蛋白及其应用 | |
| CN116096897A (zh) | 抗4-1bb-抗pd-l1双特异性抗体、其药物组合物及用途 | |
| CN116261595A (zh) | 抗vegf-抗pd-l1双特异性抗体、其药物组合物及用途 | |
| WO2006020258A2 (en) | Novel tetravalent bispecific antibody | |
| JP2023519440A (ja) | 多重特異性抗体構築のためのプラットフォーム | |
| WO2018166507A1 (zh) | 新型重组双功能融合蛋白及其制备方法和用途 | |
| EP2603527A1 (en) | Humanized egfr antibodies | |
| JP2025524429A (ja) | Ｄｌｌ３とｃｄ３に特異的に結合する抗原結合分子及びその医薬的使用 | |
| JP7812988B2 (ja) | Ｌｅｗｉｓ Ｙに対するヒト化抗体 | |
| CN114786720B (zh) | TriAx抗体的组合物及其制备和使用方法 | |
| JP2023534959A5 (enExample) | ||
| EP4435006A1 (en) | Bispecific antibody and use thereof | |
| CN118754989B (zh) | 一种抗her2纳米抗体及其制备方法和应用 | |
| TW202000908A (zh) | 針對程式性細胞死亡配體1 (pd-l1)的抗體及其應用 | |
| US20240026004A1 (en) | ANTI-PD-L1/TGF-ß BIFUNCTIONAL ANTIBODY AND USE THEREOF | |
| TW202146446A (zh) | 一種抗pd-l1和egfr的四價雙特異性抗體 | |
| WO2024131835A1 (en) | Ligand-cytotoxicity drug conjugates and pharmaceutical uses thereof | |
| WO2024173565A2 (en) | Human synthetic antibodies targeting human epidermal growth factor receptor 2 (her2) mutants | |
| HK40117294A (en) | Bispecific antibody and use thereof | |
| HK40128165A (zh) | Triax抗体的组合物及其制备和使用方法 | |
| HK40128164A (zh) | Triax抗体的组合物及其制备和使用方法 |